Payment overview · 2025
General Payments
$228.27
6 reported records · 4 companies
Healthcare provider profile · identity verified
Gregory Stefan Bevels, MD
Allopathic & Osteopathic Physicians|Family Medicine · ALEXANDRIA, LA · NPI 1750366027
Verified facts
What the public records show
CMS Open Payments records show Gregory Stefan Bevels, MD received $228.27 in general payments during 2025 across 6 reported records.
Lilly USA, LLC accounted for 54.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.98 | 54.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $58.55 | 25.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.63 | 13.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.11 | 6.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $228.27 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $124.98 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $58.55 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $29.63 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 127 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
142 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
127 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
132 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 307 | 80 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 72 |
| Gabapentin | Gabapentin | 259 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 241 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 240 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 228 | 70 |
| Potassium Chloride | Potassium Chloride | 222 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 218 | 66 |
| Montelukast Sodium | Montelukast Sodium | 206 | 64 |
| Losartan Potassium | Losartan Potassium | 202 | 53 |
| Pioglitazone Hcl | Pioglitazone Hcl | 197 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 170 | 49 |
| Tramadol Hcl | Tramadol Hcl | 155 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 148 | 37 |
| Jardiance | Empagliflozin | 142 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 141 | 40 |
| Trulicity | Dulaglutide | 132 | 23 |
| Mounjaro | Tirzepatide | 127 | 23 |
| Alprazolam | Alprazolam | 122 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 40 |
| Metformin Hcl | Metformin Hcl | 117 | 28 |
| Farxiga | Dapagliflozin Propanediol | 111 | 20 |
| Furosemide | Furosemide | 111 | 30 |
| Allopurinol | Allopurinol | 109 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 26 |
| Meloxicam | Meloxicam | 104 | 25 |
| Nifedipine Er | Nifedipine | 103 | 25 |
| Omeprazole | Omeprazole | 101 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 28 |
| Metformin Hcl Er | Metformin Hcl | 92 | 25 |
| Ezetimibe | Ezetimibe | 91 | 26 |
| Ozempic | Semaglutide | 85 | 15 |
| Carvedilol | Carvedilol | 76 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 75 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 71 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 19 |
| Clonazepam | Clonazepam | 60 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 60 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 21 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 59 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 57 | 24 |
| Sertraline Hcl | Sertraline Hcl | 56 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 14 |
| Famotidine | Famotidine | 53 | 14 |
| Prednisone | Prednisone | 53 | 43 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 52 | 16 |
| Celecoxib | Celecoxib | 51 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 17 |
| Ibuprofen | Ibuprofen | 50 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 14 |
| Fluconazole | Fluconazole | 48 | 31 |
| Bupropion Xl | Bupropion Hcl | 45 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 37 | suppressed |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Eliquis | Apixaban | 35 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 14 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 35 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 15 |
| Lisinopril | Lisinopril | 34 | 11 |
| Lorazepam | Lorazepam | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 32 | 11 |
| Indapamide | Indapamide | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Linzess | Linaclotide | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Febuxostat | Febuxostat | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Cefadroxil | Cefadroxil | 13 | 12 |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 12 |
| Novolog | Insulin Aspart | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $228.27 · 6 records | Lilly USA, LLC | Auvelity, CAPLYTA, MOUNJARO, VRAYLAR | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error